Enanta Pharmaceuticals Stock Price. Everything You Need To Know About The Enanta Pharmaceuticals Stock!
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 160 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs, with an emphasis on treatments for viral infections. Its primary wholly owned research and development programs are in virology, namely respiratory syncytial virus (RSV), SARS-CoV-2, Hepatitis B virus (HBV) and Human metapneumovirus (hMPV). The firm has discovered glecaprevir, the second of two protease inhibitors discovered and developed for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is a co-formulated direct-acting antiviral (DAA), combination treatment for HCV, which is marketed under the tradenames MAVYRET and MAVIRET. Its lead clinical candidate for the treatment of chronic infection with HBV, is EDP-514. Its lead clinical candidate for COVID-19 is EDP-235. The firm’s clinical stage program for RSV, with two compounds in clinical trials includes EDP-938 and EDP-323.
Enanta Pharmaceuticals Stock Price. Everything You Need To Know About The Enanta Pharmaceuticals Stock! performance
- Employees 160
- Company HQ Watertown
- Website https://www.enanta.com/
- ENTA Asset Type Common Stock
- ENTA Market Capitalization 261.7M
- Earnings Per Share -6.57
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth -0.662
Are you interested in investing in Enanta Pharmaceuticals but not sure where to start from Malaysia, Thailand, Indonesia, or Vietnam? Look no further! Enanta Pharmaceuticals is a groundbreaking biotechnology company that specializes in the development of novel small molecule drugs for the treatment of viral infections and liver diseases. With a reputation for innovation and a strong pipeline of potential blockbuster drugs, Enanta Pharmaceuticals presents an exciting investment opportunity for retail investors in Southeast Asia. But how can you get started? At Zorion, we provide comprehensive investment insights and recommendations specifically tailored to the needs of retail investors from Malaysia, Thailand, Indonesia, and Vietnam. Our platform offers access to real US stocks, including Enanta Pharmaceuticals, as well as educational resources to further enhance your investment knowledge. Start investing in Enanta Pharmaceuticals and diversify your portfolio with Zorion today!
